Showing 2391-2400 of 5909 results for "".
- OcuTerra Completes Enrollment in Phase 2 DR:EAM Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathyhttps://modernod.com/news/ocuterra-completes-enrollment-in-phase-2-dream-trial-of-topically-delivered-ott166-in-adults-with-diabetic-retinopathy/2481732/OcuTerra Therapeutics announced full enrollment in the company’s phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating topically delivered OTT166 eye drops in adult patients with moderately severe to severe nonproliferative diabeti
- Caeregen Therapeutics Receives $1.4 Million Phase 2 SBIR Grant from NIH/NEI to Advance Development of Noregen for Retinal Diseaseshttps://modernod.com/news/caeregen-therapeutics-receives-14-million-phase-2-sbir-grant-from-nihnei-to-advance-development-of-regenerative-medicine-clinical-candidate-ctr-107-noregen-for-retinal-diseases/2481729/Caeregen Therapeutics announced that it has been awarded a $1.4 million phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute (NEI) to advance the development of CTR-107 (Noregen), a regenerative therapeutic for the treatme
- Dean Burns Named President and CEO of Ocumeticshttps://modernod.com/news/dean-burns-named-president-and-ceo-of-ocumetics/2481722/Ocumetics Technology has appointed ophthalmic executive Dean Burns as President and CEO. Mr. Burns, whoj will also join the Ocumetics board of directors, was previously a consultant for Ocumetics, assisting with regulatory and marketing endeavours. Mr. Burns replaces 
- Nicox Presents NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis at the World Glaucoma Congresshttps://modernod.com/news/nicox-presents-ncx-470-phase-3-mont-blanc-adaptive-design-data-and-additional-subset-analysis-at-the-world-glaucoma-congress/2481705/Nicox presented additional data on NCX 470 at the 10th World Glaucoma Congress (WGC) in Rome, Italy. “The large volume of data generated in the Mont Blanc phase 3 trial on NCX 470 has provided us with the opportunity to look in detail at patient subgroups to further
- UnitedHealthcare Launches Virtual Prescription Renewal Option for Contact Lenses and Glasseshttps://modernod.com/news/unitedhealthcare-launches-virtual-prescription-renewal-option-to-help-members-renew-contact-lenses-and-glasses/2481688/UnitedHealthcare has introduced a new virtual prescription renewal option for the millions of members enrolled in its eligible employer-sponsored vision plans. The renewal option aims to make it more convenient and accessible for plan participants to obtain contact lenses and glasses from th
- FDA Clearance Expands the Label of Eyenuk's EyeArt AI System for the Detection of DRhttps://modernod.com/news/fda-clearance-expands-the-label-of-eyenuks-eyeart-ai-system-for-the-detection-of-dr/2481685/Eyenuk has received FDA clearance to use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy (DR), adding to the already-cleared usage with Canon CR-2 AF and Canon CR-2 Plus AF cameras. The regulatory clearance of t
- New Analysis From N-MOmentum Clinical Trial of Uplinza Demonstrate Process that Could Improve Clinical Care Process for NMOSDhttps://modernod.com/news/new-analysis-from-n-momentum-clinical-trial-of-uplinza-demonstrate-process-that-could-improve-clinical-care-process-for-nmosd/2481680/Horizon Therapeutics announced the publication of a new analysis from the N-MOmentum clinical trial of Uplinza demonstrating the utility of an adjudication process that could improve clinical care decision-making in neuromyelitis optica spectrum disorder (NMOSD) through more accurate and consiste
- Study: Lab-Grown ‘Mini-Corneas’ Mimic Developing Human Corneashttps://modernod.com/news/study-lab-grown-mini-corneas-mimic-developing-human-corneas/2481678/Researchers at NYU Langone Health say three-dimensional, lab-grown “mini-corneas” resemble the developing human cornea, potentially making them a new tool for the study of corneal diseases. P
- Beacon Therapeutics Launches with Goal of Developing Gene Therapies for Retinal Diseaseshttps://modernod.com/news/beacon-therapeutics-launches-with-goal-of-developing-gene-therapies-for-retinal-diseases/2481673/Beacon Therapeutics has launched and will develop a new generation of gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness. Syncona Limited, with additional investors including OSE, has provided £96 million ($120 million) to fund the acqu
- FDA Clears CorNeat EverPatch, World's First Non-Degradable, Synthetic Tissue Substitute for Ophthalmic Surgeryhttps://modernod.com/news/fda-clears-corneat-everpatch-worlds-first-non-degradable-synthetic-tissue-substitute-for-ophthalmic-surgery/2481668/The FDA has granted 510(k) clearance to CorNeat Vision's EverPatch, which the company describes as the first synthetic, non-degradable tissue-integrating matrix for use in ophthalmic surgeries. It is composed of a non-woven, polymer matrix which integrates with surrounding tissue an